The stock of Udg Healthcare PLC (LON:UDG) hit a new 52-week high and has GBX 991.56 target or 47.00% above today’s GBX 674.53 share price. The 5 months bullish chart indicates low risk for the GBX 1.66 billion company. The 1-year high was reported on Nov, 9 by Barchart.com. If the GBX 991.56 price target is reached, the company will be worth GBX 780.20M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 0.23% or GBX 1.53 on November 9, hitting GBX 674.53. About 348,017 shares traded hands. Udg Healthcare PLC (LON:UDG) has risen 8.90% since April 11, 2016 and is uptrending. It has outperformed by 4.12% the S&P500.
Udg Healthcare PLC (LON:UDG) Ratings Coverage
Out of 9 analysts covering UDG Healthcare PLC (LON:UDG), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. UDG Healthcare PLC has been the topic of 40 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, June 24 by Numis Securities. The rating was maintained by Jefferies on Wednesday, November 4 with “Buy”. Berenberg maintained the shares of UDG in a report on Monday, July 25 with “Buy” rating. The stock has “Hold” rating given by Berenberg on Friday, October 16. The firm has “Buy” rating given on Friday, February 12 by Berenberg. The rating was maintained by Jefferies on Tuesday, December 15 with “Buy”. On Tuesday, November 24 the stock rating was maintained by Jefferies with “Buy”. Goodbody maintained Udg Healthcare PLC (LON:UDG) on Friday, April 1 with “Buy” rating. The rating was maintained by Davy Research with “Outperform” on Thursday, August 4. The firm earned “Hold” rating on Thursday, August 6 by N+1 Singer.
UDG Healthcare plc, formerly United Drug plc, is a healthcare services well-known provider in the Republic of Ireland, the United Kingdom, North America and Continental Europe. The company has a market cap of 1.66 billion GBP. The Firm operates in three divisions. It has a 34.54 P/E ratio. The Ashfield Commercial & Medical Services segment is engaged in the provision of sales, marketing and healthcare communications services to pharmaceutical companies, and it also provides sales teams, healthcare communications, telesales, nurse educators, medical information, pharmacovigilance, regulatory and event management services to over 300 healthcare companies in approximately 20 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.